T-MACS – One and Done
In the original study, they used hs-TnT and heart-type fatty acid binding protein along with clinical criteria. Here is the original MACS decision aid:
- A. High sensitivity cardiac troponin T (ng/L) – Continuous variable
- B. Heart-type fatty acid binding protein (ng/mL) – Continuous
- C. ECG ischaemia – Dichotomous variable
- D. Sweating observed by the treating clinician – Dichotomous
- E. Vomiting in association with the presenting symptoms – Dichotomous
- F. Systolic BP <100 mm Hg on arrival – Dichotomous
- G. Worsening (or crescendo) angina – Dichotomous
- H. Pain radiating to the right arm or shoulder – Dichotomous
They reanalyzed the data with just hs-TnT, dropping the heart-fatty-protein-acid-bindy-thingy (whatever that was…). There was a derivation and subsequent validation of this diagnostic decision aid at 3 external locations. The primary outcome was acute coronary syndrome (ACS), “defined as prevalent acute myocardial infarction (AMI) or incident death, AMI or coronary revascularisation within 30 days.” They found T-MACS to have 99.3% NPV and 98.1% sensitivity. It would have allowed 40% to be ruled out with one troponin.
You have got to play around with the MDCalc version of T-MACS. It is fascinating to change the variables and watch what happens to the risk percentage as dichotomous or hs-TnT continuous variables change. I have to admit, my bias is to do serial troponins, which others think is a best practice as well. It depends on your comfort level with 98% sensitivity.
T-MACS is a viable rule-out (or rule-in) option to aid clinical decision making in patients with chest pain using hs-TnT (now available in the US). Don’t miss this blog post on St. Emlyns by lead author Rick Body about this article.
Troponin-only Manchester Acute Coronary Syndromes (T-MACS) decision aid: single biomarker re-derivation and external validation in three cohorts. Emerg Med J. 2017 Jun;34(6):349-356. doi: 10.1136/emermed-2016-205983. Epub 2016 Aug 26.
Peer reviewed by Thomas Davis.